Physician profile
Anusha Mannava
NPI 1972920049
$3,438.04
in general payments reported to CMS, 2019-2025
31 companies · $2,383 in 2025
The $2,383 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.86 · 2020: $14.94 · 2022: $206 · 2023: $128 · 2024: $673 · 2025: $2,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,084 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $342.53 | 2019-2025 | |
| Tg Therapeutics, INC. | $312.07 | 2025 | |
| Abbvie INC. | $292.29 | 2024-2025 | |
| Sk Life Science, INC. | $214.38 | 2023-2025 | Xcopri |
| Biogen, INC. | $198.00 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Janssen Biotech, INC. | $190.65 | 2025 | |
| Jazz Pharmaceuticals INC. | $149.14 | 2025 | |
| Lundbeck LLC | $140.11 | 2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $139.45 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $133.79 | 2022-2025 | |
| Eisai INC. | $114.65 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $110.86 | 2022 | |
| Pfizer INC. | $109.92 | 2025 | |
| Lilly USA, LLC | $106.03 | 2020-2025 | Amyvid, Kisunla |
| Axsome Therapeutics, INC. | $101.90 | 2025 | Symbravo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $101.62 | 2025 | Rystiggo |
| Argenx US, INC. | $99.69 | 2024-2025 | Vyvgart Hytrulo |
| Ani Pharmaceuticals, INC. | $82.38 | 2024-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $77.35 | 2023-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $76.29 | 2025 | Ponvory |
| Alnylam Pharmaceuticals INC. | $73.52 | 2025 | Givlaari |
| Ge Healthcare | $54.89 | 2025 | |
| Genentech USA, INC. | $44.45 | 2025 | Ocrevus Zunovo |
| Emd Serono, INC. | $31.93 | 2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $25.68 | 2024 | Austedo Xr |
| Amgen INC. | $25.56 | 2025 | Uplizna |
| Tanabe Pharma America, INC. | $22.77 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $17.57 | 2025 | Dysport |
| Hospira, INC. | $17.28 | 2024 | |
| Livanova USA, INC. | $16.83 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $14.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anusha Mannava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.